Arkolith/Insider Trading/RPHM/Form 4

Hall Ashley

Chief Development OfficerReneo Pharmaceuticals, Inc. (RPHM) · full profile →Form 4 · filed Aug 29, 2023
Net Selling
Open-Market Buys
$0
Open-Market Sells
$98K
Net Open-Market Flow
-$98K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Aug 28, 2023Sell(S)16K$6.28$98K40K
Aug 28, 2023Option exercise(M)16K$1.80$28K55K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Aug 28, 2023Option exercise(M)16K—$0109K

Transaction Codes

S
Open-market sale
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001209191-23-047626) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML